Produkty lecznicze stosowane u ludzi

Pharmaceutical strategy for Europe

  1. Polski
  2. English

"I want you to look at ways to help ensure Europe has the supply of affordable medicines to meet its needs. In doing so, you should support the European pharmaceutical industry to ensure that it remains an innovator and world leader.“ (Mission letter of Stella Kyriakides, European Commissioner for Health and Food Safety)

People across the EU expect to benefit from equal access to safe, state-of-the-art and affordable therapies. Medicines play an important role in this regard, as they offer therapeutic options for diagnosis, treatment and prevention of diseases. Europe’s pharmaceutical sector is a major contributor to the EU economy in terms of creation of highly skilled jobs and investment in innovation.

Digitalisation and innovation in the use of real world data open new possibilities in how medicines are developed and used. However, innovative therapies do not reach all patients across Europe quickly and patients might not have access to medicines they need due to shortages. The unprecedented coronavirus pandemic further demonstrated how important it is to have a crisis-resistant system and ensure availability of medicines under all circumstances. At the same time, Europe’s population is ageing and faces a rising burden of diseases and emerging health threats such as the coronavirus. Moreover, health systems and patients have difficulty bearing the cost of medicines. The EU is also becoming increasingly dependent on third countries for importing medicines and their active ingredients and issues such as Anti-Microbial Resistance and environmental sustainability of medicines is a concern.

The Pharmaceutical strategy for Europe aims to address these issues by creating a future proof regulatory framework and support industry in promoting research and technologies that actually reach patients and fulfil their therapeutic needs while addressing market failures. It will also take into account the weaknesses exposed by the coronavirus pandemic and factor-in appropriate actions to strengthen the system.

It aims to examine legislative and non-legislative action in four specific objectives:

  • First, make sure that patients across Europe have new medicines and therapies in their countries quickly and under all circumstances and that there are fewer shortages of medicines.
  • Second, help to make medicines more affordable and increase the “value for money” of medical expenses.
  • Third, take advantage of digitalisation and make sure that innovation and emerging science and technology caters to the therapeutic needs of patients while reducing the environmental footprint.
  • Finally, reduce direct dependence on raw materials sourced from non-EU countries and influence other countries to harmonise international standards of quality and safety of medicines and help European pharmaceutical companies’ compete on the global level on an equal footing.

This initiative is in line with the new Industrial Strategy for Europe and the priorities outlined in the European Green Deal, Europe’s Beating Cancer Plan, the European Digital Strategy.

The Commission has launched an online public consultation on the Pharmaceutical strategy for Europe and welcomes your views. The consultation will be open until 15 September 2020.

Pharmaceutical Strategy: stakeholders' workshop on 14/15 July 2020

DG SANTE will organise, on 14 and 15 July, an online workshop with stakeholders in the field of medicinal products and other related areas. Interested parties - which may include but are not limited to- representatives of industry, patients, public health organisations, healthcare professionals and providers, research community etc., as well as  national authorities.

The objective of this workshop is to gather stakeholder’s views on the basis of questions in specific areas of the strategy.

If interested, please register until 3 July

Please note that due to the format of the meeting, available invitations are limited and a balanced selection of represented interests may have to be made.

Related information